[
  {
    "ts": null,
    "headline": "Zoetis Inc. stock outperforms competitors despite losses on the day",
    "summary": "Zoetis Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=abcb1c093e2dc818273b1775d79042128b75244f406afe01f53b367542cb8520",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742920980,
      "headline": "Zoetis Inc. stock outperforms competitors despite losses on the day",
      "id": 133454685,
      "image": "",
      "related": "ZTS",
      "source": "MarketWatch",
      "summary": "Zoetis Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=abcb1c093e2dc818273b1775d79042128b75244f406afe01f53b367542cb8520"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis : Announces Results from First Study Comparing Librela® (bedinvetmab injection) to the NSAID Meloxicam",
    "summary": "Librela provided equivalent efficacy to meloxicam for managing osteoarthritis pain and was associated with fewer adverse events in study. Parsippany, NJ March 24, 2025 -...",
    "url": "https://finnhub.io/api/news?id=ed6bd388bb2a034346a46d7f413c3793b5eee664297e4871053c726e39721b82",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742896812,
      "headline": "Zoetis : Announces Results from First Study Comparing Librela® (bedinvetmab injection) to the NSAID Meloxicam",
      "id": 133375149,
      "image": "",
      "related": "ZTS",
      "source": "Finnhub",
      "summary": "Librela provided equivalent efficacy to meloxicam for managing osteoarthritis pain and was associated with fewer adverse events in study. Parsippany, NJ March 24, 2025 -...",
      "url": "https://finnhub.io/api/news?id=ed6bd388bb2a034346a46d7f413c3793b5eee664297e4871053c726e39721b82"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder",
    "summary": "Zoetis operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization. Read why ZTS stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=1378ca294978cf05385ccbeead0135fec673f1fee47824276c17aa60e5dba262",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742887800,
      "headline": "Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder",
      "id": 133370577,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/543196085/image_543196085.jpg?io=getty-c-w1536",
      "related": "ZTS",
      "source": "SeekingAlpha",
      "summary": "Zoetis operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization. Read why ZTS stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=1378ca294978cf05385ccbeead0135fec673f1fee47824276c17aa60e5dba262"
    }
  }
]